Last reviewed · How we verify
Placebo of HGP0816
Placebo of HGP0816 is a Small molecule drug developed by Hanmi Pharmaceutical Company Limited. It is currently in Phase 3 development.
This is a placebo control and contains no active pharmaceutical ingredient.
At a glance
| Generic name | Placebo of HGP0816 |
|---|---|
| Sponsor | Hanmi Pharmaceutical Company Limited |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo formulation, HGP0816 placebo is an inert control used in clinical trials to establish the baseline effect of the study design and patient expectations, without any active mechanism of action. It serves as the comparator arm in phase 3 trials to isolate the true efficacy of the active investigational drug.
Approved indications
Common side effects
Key clinical trials
- Clinical Efficacy and Safety Evaluation of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia (PHASE3)
- Evaluating the Efficacy and Safety of HCP1105 in Combined Hyperlipidemic Patients With High Risk for CHD (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo of HGP0816 CI brief — competitive landscape report
- Placebo of HGP0816 updates RSS · CI watch RSS
- Hanmi Pharmaceutical Company Limited portfolio CI
Frequently asked questions about Placebo of HGP0816
What is Placebo of HGP0816?
How does Placebo of HGP0816 work?
Who makes Placebo of HGP0816?
What development phase is Placebo of HGP0816 in?
Related
- Manufacturer: Hanmi Pharmaceutical Company Limited — full pipeline
- Compare: Placebo of HGP0816 vs similar drugs
- Pricing: Placebo of HGP0816 cost, discount & access